Teva Pharmaceutical Industries (TEVA) Upgraded by ValuEngine to Buy

ValuEngine upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a buy rating in a report released on Tuesday.

Several other research analysts also recently commented on TEVA. Jefferies Group reaffirmed a hold rating and issued a $26.00 price objective (down from $33.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. Deutsche Bank reaffirmed a buy rating and issued a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. BTIG Research set a $16.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Tuesday, November 28th. Cantor Fitzgerald reaffirmed a neutral rating and issued a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. Finally, Credit Suisse Group reaffirmed an outperform rating and issued a $39.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. Seven equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $21.65.

Teva Pharmaceutical Industries (TEVA) traded down $0.83 on Tuesday, reaching $14.24. 10,600,478 shares of the company traded hands, compared to its average volume of 15,647,090. The company has a market cap of $15,290.80, a P/E ratio of 3.48 and a beta of 0.55. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.39%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is -12.10%.

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $106,000. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $129,000. Shelter Mutual Insurance Co bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $133,000. Finally, Fieldpoint Private Securities LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $171,000. 52.05% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Upgraded by ValuEngine to Buy” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/06/teva-pharmaceutical-industries-teva-upgraded-by-valuengine-to-buy.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply